Granzyme B (GzmB) is a neutral serine protease found in cytotoxic lymphocytes; this enzyme is critically involved in delivering the rapid apoptotic signal to susceptible target cells. GzmB has been difficult to study and has not yet been produced in non-mammalian systems because of the complex processing events that are thought to be required for its activation. In this report, we have successfully produced fully active, soluble recombinant GzmB (rGzmB) in a yeast-based system by fusing GzmB cDNA in frame with yeast ␣-factor cDNA, using the yeast KEX2 signal peptidase to release the processed enzyme into the supernatant of yeast cultures. We expressed the proenzyme form of GzmB as well and determined that pro-GzmB is efficiently converted to its active form by the cysteine proteinase dipeptidyl peptidase I. The fully processed enzyme was able to hydrolyze the synthetic substrate N-t-butyloxycarbonyl-L-alanyl-L-alanyl-L-aspartyl (Boc-Ala-Ala-Asp) thiobenzyl ester with a k cat of 17 s ؊1 and catalytic efficiency k cat /K m of 181,237 M ؊1 s ؊1 ; the recombinant enzyme is therefore at least twice as active as purified native GzmB. In addition, the recombinant enzyme hydrolyzes Boc-Ala-Ala-Met thiobenzyl ester with a k cat of 3.2 s ؊1 and a catalytic efficiency k cat /K m of 65,306 M ؊1 s ؊1 . Purified rGzmB can also cleave the putative substrate caspase-3 into its signature p20/p10 forms. Unlike caspases, rGzmB is not sensitive to inhibition by several peptide-based inhibitors, including Ac-DEVD-CHO, Ac-YVAD-CMK, and ZIETD-FMK, as well as Zn 2؉ (a known inhibitor of caspase-3). Structural studies of rGzmB may allow us to better understand the substrate specificity of this enzyme and to design better inhibitors.
cells, and lymphokine-activated killer (LAK) cells. The importance of GzmB for inducing target cell death has been demonstrated via several lines of evidence (reviewed in Refs. 1 and 2) and confirmed with GzmB null mutant mice (3) . CTL and NK cells derived from these mice have a severe defect in their ability to induce early DNA fragmentation and apoptosis in susceptible target cells. Furthermore, in vivo data suggest that GzmB plays a significant role in the development of acute graft-versus-host disease (4, 5) . Therefore, a specific inhibitor of GzmB may potentially prove to be an important tool in the modulation of immune responses.
Among all the known granzymes, human and murine GzmB possess an unusual preference for aspartic acid at the P1 site of its substrates (6) . This specificity is shared by only one other group of eukaryotic proteases, the caspases (reviewed in Ref. 7) . Experiments with cell-free systems and caspase inhibitors have strongly implicated these enzymes in apoptotic cell death (reviewed in Refs. 8 and 9) . Caspases are synthesized as proenzymes that generally require processing at aspartic acid residues for activation. Although the enzymes responsible for the activation of these caspases are unknown, there is evidence that these enzymes can autoactivate or cross-activate other family members (10 -13) . In vitro studies have also shown that GzmB can cleave and activate caspase-3 (CPP32) (14) , caspase-8 (FLICE) (15) , and other caspases; in addition, GzmBdeficient CTL fail to cleave caspase-3 in target cells during CTL-induced apoptosis (16) . However, these data have not determined whether GzmB induces apoptosis through the activation of caspases or whether it acts directly to induce apoptosis. Several studies have shown that peptide-based, selective caspase inhibitors (which do not inhibit GzmB) can block apoptotic cell death and target cell lysis induced by the FasFasL pathway, but not the CTL granule exocytosis (perforin/ granzyme-dependent) pathway (17, 18) .
GzmB is the prototype of a family of serine proteases (A-K) that are synthesized as preproenzymes with an 18-residue leader peptide (23 residues for granzyme A) (reviewed in Ref. 19 ). These leader peptides are thought to be cleaved by a signal peptidase, leaving a prodipeptide that must be removed to produce the active enzyme (20) . The enzyme thought to be responsible for the specific cleavage of the prodipeptide is the lysosomal cysteine protease DPPI (21) (22) (23) . Previous studies in COS cells have shown that co-transfection of a full-length (prepro) human GzmB cDNA along with a rat DPPI cDNA resulted in the generation of an enzymatically active GzmB, whereas transfection of full-length GzmB cDNA alone led to the production of a catalytically inactive enzyme (22) . In addition, recombinant granzyme A (rGzmA) can be converted into a proteolytically active enzyme by incubation with bovine DPPI (23) .
Although native GzmB (nGzmB) has been purified, only limited amounts of relatively pure enzyme have been obtained.
Previously, small amounts of rGzmB have been successfully prepared from a mammalian COS cell-based system (22, 24) . However, the inability to purify sufficient amounts of rGzmB (without any other contaminating cellular enzymes) has limited the ability to study substrate specificities and to design specific inhibitors. rGzmA has been successfully expressed in Escherichia coli (25) and vaccinia virus (23) ; however, we have repeatedly failed to generate soluble active rGzmB using a variety of expression systems.
In this study, we describe the production of a yeast-based, soluble, secreted form of active rGzmB. This recombinant protein has the same specificities as nGzmB purified from an NK tumor cell line. We showed that pro-GzmB (which contains the prodipeptide Gly-Glu) can be converted to a fully active form by bovine DPPI. The active mature rGzmB can cleave caspase-3 into its signature p20/p10 forms. We also determined that several peptide-based caspase inhibitors do not significantly inhibit the Asp'ase activity of rGzmB; furthermore, Zn 2ϩ , a potent inhibitor of caspase-3 (26), fails to inhibit rGzmB. These results underscore the fundamental differences in substrate specificities between the caspases and GzmB.
EXPERIMENTAL PROCEDURES
Production of Mature and Pro-rGzmB in Pichia pastoris-The cDNAs encoding the pro and mature forms of murine GzmB were amplified using the forward primers 5Ј-GGGGAGATCATCGGGGGGA-C-3Ј (pro) and 5Ј-ATCATCGGGGGACATGAAGC-3Ј (mature) and the reverse primer 5Ј-TTAGCTTTTCATTGTTTTCTTTATCCAGGATAAG-AAACTTGAGAC-3Ј. A 5Ј XhoI site and a 3Ј EcoRI site were introduced into the cDNAs and the products subcloned into the expression vector pPIC9 (Invitrogen, Carlsbad, CA). Both inserts were completely sequenced and found to be identical (except for the prodipeptide Gly-Glu). Both vectors were electroporated into GS115 (Invitrogen) at 1.5 KV, 50 F, and 186 ohms. His ϩ transformants were selected and induced with methanol for 4 days according to a protocol suggested by the manufacturer (Invitrogen). Daily aliquots of induced supernatants from His ϩ clones were assayed for Asp'ase activity and probed (using Western blotting) for the presence of rGzmB using a polyclonal rabbit antimouse GzmB antibody (27) . The clones expressing pro-GzmB and mature rGzmB were selected and further expanded. A liter of supernatant from each clone was precipitated using 85% ammonium sulfate, resuspended, and dialyzed to a final concentration of 250 mM NaCl in 50 mM MES, 0.1 mM EGTA, 10% betaine (MEB buffer). The concentrated supernatant was loaded onto a Mono S cation exchange column, and proteins were eluted using a linear gradient of 0.25 M NaCl to 1 M NaCl. Pro-GzmB and rGzmB both eluted at approximately 0.6 M NaCl.
Preparation of Native Murine GzmB-Murine GzmB was isolated from an NK-like tumor line derived from tumors that arose in transgenic mice expressing SV40 large T-antigen driven by the human granzyme H 5Ј-flanking promoter sequence. 2 This cell line was used because it expresses abundant murine GzmB (28) . Briefly, cells were harvested, pelleted, resuspended in 1 M NaCl, 0.1% Triton X-100, and sonicated. The crude extract was cleared by centrifugation, dialyzed to a final concentration of 250 mM NaCl in MEB buffer, and loaded onto a Mono S column. Proteins were eluted with a linear gradient of 0.25 to 1 M NaCl. Native murine GzmB eluted at approximately 0.6 M NaCl.
Western Blotting-Western analysis was performed using the polyclonal rabbit anti-murine GzmB antibody as described previously (27) . Equivalent amounts (0.5 g) of pro-GzmB, rGzmB, or purified nGzmB were used for each lane of an SDS-PAGE reducing protein gel under reducing conditions. The gels were either stained directly with the rapid silver stain kit (ICN Biomedicals, Aurora, OH) or transferred to nitrocellulose and immunoblotted with immune sera at a 1:500 dilution, as described previously (27) .
Enzyme Assays-Enzyme assays were performed using equivalent amounts of pro-GzmB, mature rGzmB, and nGzmB as determined by absorption at 280 nm and by Western blotting. Asp'ase and Met'ase assays were carried out in a 500-l volume using 3-5 l of enzyme (0.3-0.5 g) in assay buffer containing 0.1 M Hepes, pH 7.5, 0.3 M NaCl, 1 mM EDTA, 0.11 mM dithiobis(2-nitrobenzoic acid) (DTNB) (Sigma), and 0.1 mM substrate. Reactions were incubated at 23°C for 30 min, and color development was measured at A 405 nm . Background (nonenzymatic) hydrolysis of substrates was assayed using 5 l of MEB buffer in the same assay buffer, including substrate and DTNB. Tryptase assays were performed in a 200-l volume using 0.3-0.5 g of enzyme in phosphate-buffered saline, pH 7.5, containing 0.22 mM DTNB, 0.20 mM N-␣-benzylcarbonyl-L-lysine thiobenzyl ester (BLT), and 0.01% Triton X-100. Reactions were incubated at 37°C for 20 min and stopped by adding 1 ml of 1 mM phenylmethylsulfonyl fluoride; color development was measured at A 412 nm . Protease substrates included: Boc-Ala-Ala-Asp-S-benzyl (Enzyme Systems Products, Dublin, CA) for Asp'ase activity; Boc-Ala-Ala-Met-S-benzyl (Enzyme Systems Products) for Met'ase activity; Boc-Ala-Ala-Phe-S-benzyl (Enzyme Systems Products) for chymase activity; Z-Lys-S-benzyl (Calbiochem) for tryptase activity. Protease inhibitors included: Z-Ile-Glu-Thr-Asp-FMK (Enzyme Systems Products), Ac-Asp-Glu-Val-Asp-CHO (Bachem, Torrance, CA), Ac-Tyr-Val-Ala-Asp-CMK (Calbiochem), and 3,4-dichloroisocoumarin (Calbiochem). Stock solutions of substrates and inhibitors were prepared in Me 2 SO and stored at Ϫ70°C.
Determination of Substrate Kinetics-Equivalent amounts of rGzmB and nGzmB were defined by Western analysis. The initial rates of hydrolysis were measured at 412 nm (⑀ 412 ϭ 14,150 M Ϫ1 cm
Ϫ1
) using a Cary 3 UV-visible spectrophotometer (Varian, Sugarland, TX) after 10 l (0.043 M) of enzyme stock solution was added to a cuvette containing 1.0 ml of buffer, 0.33 mM DTNB, and 40 l of substrate (10 -500 M) at 20°C. After substraction for background hydrolysis, measurements were plotted using a KaleidaGraph program (Synergy, Reading, PA), and the K m and k cat for each substrate were determined using the Michaelis-Menten equation. Correlation coefficients for all plots were Ͼ0.99.
Endoglycosidase H (Endo H) Digestion-Endo H treatment of proteins to remove N-linked oligosaccharides was performed in 100-l reactions using 5 l (0.5 g) of pro-GzmB, rGzmB, or nGzmB in an assay buffer containing 75 mM sodium citrate, pH 5.5, and 5 l of 1 unit/ml Endo H (Sigma). Negative controls were performed using 5 l of MEB buffer with or without Endo H. The reactions were allowed to incubate overnight at 37°C. Ten l of the reaction products were analyzed on SDS-PAGE gels and immunoblotted. Fifty l of the reaction products were used to assay for Asp'ase activity with Boc-Ala-AlaAsp-S-benzyl as the substrate.
Pro-GzmB Activation by DPPI-5 l (0.5 g) of pro-GzmB was incubated with 0.1-0.4 unit of purified bovine spleen DPPI (Sigma) in 50 l of assay buffer containing 50 mM sodium acetate, pH 5.0, 30 mM NaCl, 1 mM EDTA at 37°C overnight. The reaction was diluted 10-fold in Asp'ase buffer, and Asp'ase activity was measured as described above with Boc-Ala-Ala-Asp-S-benzyl as the substrate. The activity was compared with the activity of equivalent amounts of active rGzmB. For inhibition studies, DPPI was incubated with varying concentrations of glycine-phenylalanine-diazomethylketone (G-F-CHN 2 ) (29), a potent and specific inhibitor of DPPI, for 2 h prior to the addition of pro-GzmB. The reactions were then allowed to proceed overnight as described above. To control for any direct effect of G-F-CHN 2 on Asp'ase activity, active rGzmB was also incubated with G-F-CHN 2 prior to the activity assay.
CPP32 in Vitro Translation and Activation-mCPP32 cDNA was generated by reverse transcription-polymerase chain reaction using RNA derived from GzmB-deficient CTL effectors (3). RNA was prepared as described (30) . Approximately 1 g of RNA was incubated with 200 ng of oligo(dT) 16 and 50 ng of random hexamers (Perkin-Elmer) for 10 min at 68°C. After 2 min on ice, 10 mM dNTPS, 100 mM dithiothreitol, 0.5 l of SuperScript reverse transcriptase (Life Technologies, Inc.) was added and incubated at 37°C for an hour. After adjusting the total volume to 100 l with diethyl pyrocarbonate water, 1 l of the first strand cDNA was used as template. The 833-base pair cDNA was then amplified using the forward primer 5Ј-GATCTCTAGAGGAACGCTAA-GAAAAGTGACCATGG-3Ј (containing an XbaI site) and the reverse primer 5Ј-GATCAAGCTTCCTCTAGTGATAAAAGTACAGTTCTTTC-G-3Ј (containing a HindIII site) and subcloned into XbaI-HindIII cleaved pBSKS (Stratagene, La Jolla, CA). 35 S-Labeled mCPP32 was obtained using T7 quick coupled transcription/translation system (Promega, Madison, WI). One g of the plasmid DNA was transcribed and translated in the presence of 20 Ci of Trans 35 S-labeled amino acids (ICN, Costa Mesa, CA) and 40 l of the TnT Master Mix for 90 min at 30°C. Two l of the translated mixture was either incubated alone, in the presence of equivalent amounts of rGzmB or pro-GzmB (as determined by Western) or in the presence of 25 g of total protein from an NK-like tumor cell line extract (which contains native GzmB), or from an extract prepared from GzmBϪ/Ϫ CTL effectors. These extracts were generated and prepared as described previously (27) . After 2 h at 37°C, the samples were analyzed on 2 D. MacIvor and T. J. Ley, submitted for publication. a 10% SDS-PAGE reducing gel. The gel was then fixed, treated with Amplify (Amersham Corp.), and autoradiographed for 2 days.
RESULTS AND DISCUSSION
P. pastoris is a methanotrophic yeast that has been successfully used to produce large quantities of foreign proteins (reviewed in Refs. 31 and 32). A major advantage of the P. pastoris expression system is that the foreign protein can be secreted (along with very low levels of native proteins) as the first step of purification. In addition, the secreted proteins are frequently correctly folded and not hyperglycosylated (33) . We designed two GzmB expression vectors for expression in Pichia: the first form included the codons for the activation dipeptide Gly-Glu (pro-GzmB); the second form starts with the Ile codon at the N terminus of the processed enzyme (rGzmB) (see Fig. 1A ). These cDNAs were cloned in frame with the ␣-factor signal peptide in pPIC9, which targets them to the secretory pathway. The expressed proteins also contain the KEX2 recognition sequence Glu-Lys-Arg directly preceding Gly-Glu (pro-GzmB) or Ile-Ile (rGzmB), which allows signal peptide cleavage by the endogenous yeast peptidase KEX2 (34) (Fig. 1A) . The supernatant from clones that expressed cleaved pro-GzmB and rGzmB were purified on a Mono S cation exchange column according to the "Experimental Procedures." The major species detected on silver-stained gels (Fig. 1B) and in Western analysis (Fig. 1C ) (using reducing conditions) had apparent molecular masses of 30 and 32 kDa. These two bands represent different glycosylated isoforms of the proteins, since Endo H treatment altered the migration of pro-GzmB and rGzmB (as well as nGzmB purified from NK-like cell lines) to approximately 25 kDa (Fig.  1C) , the predicted molecular mass of the mature protein. The deglycosylated forms of rGzmB and nGzmB retained full activity toward thiobenzyl ester substrates (data not shown). The final yield of purified rGzmB from 1 liter of yeast culture was approximately 1 mg.
The activity of each recombinant protein was determined using thiobenzyl ester substrates with the same amount of test enzyme, as demonstrated by silver stain and Western analysis (Fig. 1, B and C ). An equivalent amount of partially purified nGzmB served as positive control. Pro-GzmB had no measurable Asp'ase activity (Table I and Fig. 4) ; in contrast, rGmB was fully active. To further quantitate the catalytic efficiency of our active recombinant enzyme, we determined MichaelisMenten parameters for two known synthetic thiobenzyl ester substrates of nGzmB. rGzmB hydrolyzed Boc-Ala-Ala-Asp-Sbenzyl with an apparent k cat of 17 s Ϫ1 and a k cat /K m of 181,237 (Table I ). The catalytic efficiency of rGzmB is approximately twice that of nGzmB; these values are similar to those reported in the literature by Odake et al. (6) and Poe et al. (35) . Similarly, rGzmA is more active than native GzmA purified from granules (25) .
Previous studies could not determine whether the Met'ase activity detected in purified GzmB preparations was due to GzmB itself or to another unidentified granzyme that coeluted with GzmB (6). We definitively established that rGzmB hydrolyzes Boc-Ala-Ala-Met-S-benzyl with a k cat of 3.2 s Ϫ1 and a k cat /K m of 65,306 M Ϫ1 s Ϫ1 . Again, the catalytic efficiency of rGzmB as a Met'ase is twice that of nGzmB. The cleavage of Boc-Ala-Ala-Met-S-benzyl suggests that there may be GzmB substrates with Met at the P1 position instead of an Asp. rGzmB has no detectable tryptase or chymase activity (Table  I) , consistent with previous reports (6) .
To our knowledge, caspase-3 is the only caspase that has been shown to be a substrate of GzmB both in vitro as well as in vivo (12, 14) . Caspase-3 presumably exists in all cells in its inactive, 32-kDa proenzyme form. During CTL-mediated attack on susceptible target cells, nGzmB processes caspase-3 to its active p20/p10 heterodimeric form (12, 36) . For this reason, we wished to demonstrate that rGzmB is capable of recognizing and cleaving this physiological substrate. 35 S-Labeled caspase-3 was cleaved to its signature p20 form by both nGzmB as well as rGzmB (Fig. 2, lanes 3 and 4) , whereas neither pro-GzmB nor extracts from CTL effectors deficient in GzmB   FIG. 1 . Production of recombinant GzmB. A, the sites of cleavage by the signal peptidase (SP) (to generate pro-GzmB) and by DPPI (to generate GzmB) for the native prepro-GzmB are shown. The plasmids for recombinant pro-GzmB and GzmB contain the yeast ␣-factor signal peptide followed by the sequence Glu-Lys-Arg, which is recognized by the endogenous yeast enzyme KEX2. B, silver-stained gel showing the two different glycosylated isoforms of recombinant pro-GzmB and rGzmB, compared with purified nGzmB. Five l of pro-GzmB and rGzmB, versus 10 l of nGzmB purified from a Mono S column, were loaded per lane. C, Western blot analysis of the same three GzmB forms, probed with rabbit anti-mouse GzmB antibody. D, Western blot analysis of Endo H treatment of pro-GzmB, rGzmB, and nGzmB. Control samples were treated identically except that no Endo H was added. were capable of processing caspase-3 (Fig. 2, lanes 2 and 5) .
Previous studies have shown that two peptides (Ac-DEVD-CHO (37) and Ac-YVAD-CHO or Ac-YVAD-CMK (38, 39) ) are potent inhibitors of caspase-3 and caspase-1, respectively. A recent study, using a combinatorial approach, defined the tetrapeptide IEPD as an optimal substrate sequence for GzmB (40) . We therefore tested the ability of Ac-DEVD-CHO, Ac-YVAD-CMK, and ZIETD-FMK (a fluoromethyl ketone that closely matches the optimal substrate for GzmB) to inhibit rGzmB. We found that these peptides have essentially no inhibitory effect on rGzmB (or nGzmB) at concentrations up to 800 M (Fig. 3) . It should be noted that the methyl side chains added to ZIETD-FMK to enhance cell permeability might have affected the ability of this peptide to inhibit GzmB in vitro. Prolonged preincubation of the peptides with rGzmB (up to 4 h) did not increase the inhibition (data not shown). 3,4-Dichloroisocoumarin (DCI), a general serine protease inhibitor (4), inhibits rGzmB with an IC 50 value of approximately 5 M (Fig. 3) . We also tested the inhibitory effect of Zn 2ϩ (a potent inhibitor of caspase-3 with an IC 50 of 0.1 M (26)) and found that Zn 2ϩ has no effect on rGzmB at concentations up to 300 M. Other cations such as Cu 2ϩ , Mg 2ϩ , Mn 2ϩ , Fe 3ϩ , and Ca 2ϩ also had no effect on the activity of rGzmB (data not shown).
The ability of GzmB to cleave caspases, and the similarities between the specificities of GzmB and caspases (especially the requirements for Asp in the P1 position and Glu in the P4 position (40)), have suggested that GzmB is an integral part of the caspase cascade leading to cell death. However, more recent reports using specific caspase inhibitors suggest that GzmB may lead to target cell death through a caspase-independent pathway (16) . These reports, and our results with peptide and cation inhibitors, underscore the differences between the two classes of enzymes. Although the sequence IEPD may be an optimal substrate for GzmB in vitro, specific inhibition of GzmB may require additional residues beyond the P4-P1 positions. GzmB, along with the other cytotoxic lymphocyte granzyme family members, is synthesized as a preproenzyme with an 18 residue signal peptide followed by an activation dipeptide Gly-FIG. 2. mCPP32 is processed to its signature p20 form by rGzmB in vitro. In vitro translated, 35 S-mCPP32 was incubated for 2 h at 37°C alone (lane 1), with equivalent concentrations of pro-GzmB or mature, rGzmB (lanes 2 and 3, respectively), with 25 g of NK cell line-derived, total protein extract containing nGzmB (lane 4), or with 25 g of total protein extract from GzmBϪ/Ϫ CTL effectors (lane 5). Samples were run on a 10% SDS-PAGE gel, fixed, dried, and autoradiographed for 2 days.
FIG. 3.
Effects of peptide-based inhibitors on the activity of rGzmB. 0.5 g of rGzmB was added to buffer containing the indicated concentrations of inhibitors and incubated for 30 min at room temperature. Reactions were then initiated by adding the substrate Boc-AlaAla-Asp-S-benzyl to a final concentration of 100 M and allowed to proceed for an additional 30 min at room temperature. Asp'ase activity was measured at A 405 nm ; the activity measured in the absence of inhibitor was set at 100%. Ⅺ, dichloroisocoumarin; छ, DEVD; E, IETD; ‚, YVAD.
FIG. 4. Activation of pro-GzmB by bovine DPPI.
A, equivalent amounts of pro-GzmB and rGzmB were incubated with the indicated amounts of bovine DPPI or with buffer alone. Asp'ase activity was measured after overnight incubation at 37°C. DPPI alone has no Asp'ase activity. B, DPPI was preincubated with 0.6 -6 mM G-F-CHN 2 or with buffer alone for 2 h. Pro-GzmB was then added and the reactions allowed to proceed overnight. Asp'ase activity was then measured as described. G-F-CHN 2 alone had no effect on pro-GzmB, rGzmB, or the Asp'ase assay itself.
Glu. Activation requires processing of the signal peptide and the activation dipeptide. This dual proteolytic processing pathway appears to apply to the other granzymes, as well as structurally related serine proteases expressed in other hematopoietic cells such as neutrophil elastase, cathepsin G (21), and mast cell chymases (29) . The enzyme involved in the proteolytic processing of the prodipeptide is thought to be the lysosomal cysteine protease DPPI (21) (22) (23) 29) . Previous reports on the processing of rGzmB by purified bovine DPPI demonstrated specific (but low level) conversion to the active form of GzmB. Possible explanations include cross-species differences in substrate specificities (i.e. bovine DPPI processing human GzmB), inefficient subcellular colocalization of the two enzymes in transiently transfected COS cells or a requirement for an unidentified granule component to stabilize the proenzyme (20) . We therefore tested the ability of bovine DPPI to process recombinant pro-GzmB to its active form in vitro. We found that at pH 5.0, bovine DPPI efficiently activated pro-GzmB; the degree of activation appears to depend only on the concentration of exogenous DPPI added (Fig. 4A) . DPPI itself has no effect on the Asp'ase assay, nor does it affect the activity of mature rGzmB (Fig. 4A ). This suggests that once the prodipeptide is removed, mature GzmB is resistant to further proteolytic cleavage by DPPI. The activation process is inhibited by the highly specific DPPI inhibitor Gly-Phe-CHN 2 (29) , at concentrations as low as 0.6 M (Fig. 4B) . These results, and previous reports (22) (23) , indicate that DPPI alone is sufficient for the activation of pro-GzmB. A null mutation of DPPI created by homologous recombination in the mouse should confirm the importance or redundancy of this enzyme for the activation of the granzymes and related proteins.
In summary, this study is the first to demonstrate expression of active rGzmB in a non-mammalian system. The enzyme expressed has the same substrate specificities as the purified native enzyme. Inhibition studies also show that the current peptide-based inhibitors of caspases are ineffective at blocking the activity of GzmB. The Pichia system will allow us to produce large amounts of pure recombinant GzmB for structural studies that may allow us to better define substrate specificities and requirements for GzmB inhibition.
